APA (7th ed.) Citation

Okai, A. F., Amezcua, L., Berkovich, R. R., Chinea, A. R., Edwards, K. R., Steingo, B., . . . Williams, M. J. (2019). Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study). Neurology & Therapy, 8(2), 367. https://doi.org/10.1007/s40120-019-00159-2

Chicago Style (17th ed.) Citation

Okai, Annette F., et al. "Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)." Neurology & Therapy 8, no. 2 (2019): 367. https://doi.org/10.1007/s40120-019-00159-2.

MLA (9th ed.) Citation

Okai, Annette F., et al. "Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)." Neurology & Therapy, vol. 8, no. 2, 2019, p. 367, https://doi.org/10.1007/s40120-019-00159-2.